Vosoritide · VOXZOGO

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Achondroplasia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Hypochondroplasia · Phase 3 · investigational in the US · filing submitted

Also approved (2)
JP
  • Achondroplasia in children whose growth plates are not closed
Product first approved 2022biomarin.com
EU
  • Achondroplasia in patients 4 months of age and older whose epiphyses are not closed
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Achondroplasia
Hypochondroplasia
NCT07073014 · BioMarin Pharmaceutical
2025-06-20 – 2044-10 · Hypochondroplasia
What this study did
Phase 2 (10)
Achondroplasia
NCT03989947 · BioMarin Pharmaceutical
2019-06-12 – 2038-05 · Achondroplasia
What this study did
NCT02724228 · BioMarin Pharmaceutical
2016-01-26 – 2028-02 · Achondroplasia
What this study did
NCT04554940 · BioMarin Pharmaceutical
2020-10-10 – 2027-12 · Achondroplasia
What this study did
NCT03583697 · BioMarin Pharmaceutical
2018-06-13 – 2022-01-26 · Achondroplasia
What this study did
NCT02055157 · BioMarin Pharmaceutical
2014-01-13 – 2017-10-02 · Achondroplasia
What this study did
Hypochondroplasia
NCT07126262 · BioMarin Pharmaceutical
2025-07-30 – 2028-06-30 · Hypochondroplasia
What this study did
Other / comorbidity
NCT06382155 · BioMarin Pharmaceutical
2024-10-21 – 2036-12 · Idiopathic Short Stature
What this study did
NCT04219007 · Andrew Dauber
2020-08-04 – 2035-06-01 · Short Stature
What this study did
NCT06668805 · BioMarin Pharmaceutical
2024-11-22 – 2026-10-16 · Noonan Syndrome
What this study did
NCT05849389 · Roopa Kanakatti Shankar, MBBS, MS
2024-04-12 – 2026-09 · Turner Syndrome, Short Stature
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05845749 · University of California, San Francisco
2023-09-25 – 2029-12-31 · MPS IVA, MPS VI
What this study did
Phase 1 (2)
Achondroplasia
NCT05813314 · BioMarin Pharmaceutical
2023-03-15 – 2023-06-14 · Achondroplasia
What this study did
NCT01590446 · BioMarin Pharmaceutical
2012-02 – 2012-06 · Achondroplasia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (1)
Achondroplasia
NCT07441876 · BioMarin Pharmaceutical
2026-04-20 – 2029-09 · Achondroplasia
What this study did

Competitive landscape

This drug's own stage for Achondroplasia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vosoritide (VOXZOGO): this drugApprovedPeptideNatriuretic peptide receptor B (NPR-B)Reliable signal
NCT03197766: Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 (At Baseline and Week 52): BMN 111 - 15 μg/kg 1.71 cm/year (95% CI 1.4 to 2.01) | Placebo 0.13 cm/year (95% CI -0.18 to 0.45)
BMN 333Phase 2/3PeptideC-type natriuretic peptide (CNP) pathwaynot yet gradedNo reviewed efficacy summary in this indication
LavengratinibPhase 1/2Small moleculeFGFR2 / FGFR3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow VOXZOGO (Vosoritide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
Phase 2AchondroplasiaActive not recruiting
Est. primary completion 2027-12 · NCT04554940 · CT.gov ↗
What to watch
Phase 2AchondroplasiaActive not recruiting
Est. primary completion 2027-12 · NCT02724228 · CT.gov ↗
What to watch
2028 (2)
June 2028 (1)
Phase 2HypochondroplasiaRecruiting
Est. primary completion 2028-06-30 · NCT07126262 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2MPS IVA, MPS VIActive not recruiting
Est. primary completion 2028-12-31 · NCT05845749 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 3AchondroplasiaActive not recruiting
Est. primary completion 2031-06 · NCT03424018 · CT.gov ↗
What to watch
2038 (1)
May 2038 (1)
Phase 2AchondroplasiaActive not recruiting
Est. primary completion 2038-05 · NCT03989947 · CT.gov ↗
What to watch
2044 (1)
October 2044 (1)
Phase 3HypochondroplasiaEnrolling by invitation
Est. primary completion 2044-10 · NCT07073014 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 February 2027FDA action dateVOXZOGO achondroplasia sNDA (long-term data) PDUFA target action date
US, FDA · BioMarin Pharmaceutical · Source ↗

Recent

9 September 2026Filing submittedBioMarin announces it has submitted an sNDA to the FDA for VOXZOGO (vosoritide) in hypochondroplasia (announced 2026-09-09; submission date not disclosed)
US, FDA · BioMarin Pharmaceutical · Source ↗
20 May 2026Topline resultPhase 3 CANOPY-HCH-3 (NCT06455059) of vosoritide in children with hypochondroplasia met its primary endpoint (annualized growth velocity at week 52)
BioMarin Pharmaceutical · Source ↗